Will Kane has over three decades of biopharmaceutical leadership experience, with a proven track record of building high-performing teams, leading through transformational changes, and delivering exceptional business results across a wide range of therapeutic areas. Will is currently the CEO of Uniquity Bio, a clinical stage biopharmaceutical company advancing solrikitug, a treatment in development for both respiratory and gastrointestinal diseases. He previously served as President and Chief Commercial Officer of Anthos Therapeutics, where he led the operational scale up of the company and the pre-commercialization work on abelacimab, and helped drive the recent acquisition of Anthos by Novartis. Prior to that, Will was the Chief Commercial Officer at Karuna Therapeutics, where he was responsible for the commercialization strategy and plan for Cobenfy and played a key role in preparing the company for its next phase of growth.
Before joining Karuna, Will led the commercial organization at BioXcel Therapeutics, where he helped build the company and secure over $300M in capital investment. Earlier in his career, Will held senior leadership roles at Allergan, where he led the General Medicine division with over $5.8B in revenue and was responsible for the launches of Namzaric, Vraylar, and Ubrelvy; and Pfizer, where he was instrumental in the success of multiple blockbuster products, including Zoloft, Zyrtec and Celebrex.
Will received his MBA from The Wharton School at the University of Pennsylvania and a B.A. in Government from Connecticut College.
